| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| Company: Capio BioSciences |
| Recipient: An Immediate Family Member |
| Company: Archimmune Therapeutics |
| Recipient: An Immediate Family Member |
|
| Stock and Other Ownership Interests |
| Company: Capio Biosciences |
| Recipient: An Immediate Family Member |
| Company: Archimmune Therapeutics |
| Recipient: An Immediate Family Member |
| Company: Nanorobotics |
| Recipient: An Immediate Family Member |
|
| Honoraria |
| Company: Exelixis |
| Recipient: You |
| Company: Genentech/Roche |
| Recipient: You |
| Company: MJH Life Sciences |
| Recipient: You |
| Company: Pacific Genuity |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Janssen |
| Recipient: You |
| Company: Genentech/Roche |
| Recipient: You |
| Company: Sanofi |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Foundation Medicine |
| Recipient: You |
| Company: Pharmacyclics |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Seattle Genetics |
| Recipient: You |
| Company: Dendreon |
| Recipient: You |
| Company: Calithera Biosciences |
| Recipient: You |
|
| Speakers' Bureau |
| Company: Exelixis |
| Recipient: You |
| Company: Genentech/Roche |
| Recipient: You |
| Company: Genomic Health |
| Recipient: You |
| Company: Sanofi/Aventis |
| Recipient: You |
|
| Research Funding |
| Company: Astellas Pharma |
| Recipient: You |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Acerta Pharma |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Merrimack |
| Recipient: Your Institution |
| Company: Stem CentRx |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: OmniSeq |
| Recipient: Your Institution |
| Company: Personal Genome Diagnostics |
| Recipient: Your Institution |
| Company: Regeneron |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Mirati Therapeutics |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Circulating tumor cell novel capture by c-MET technology |
| Recipient: Your Institution |
| Please describe: Prochelators as Targeted Prodrugs for Prostate Cancer |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Acerta Pharma |
| Recipient: You |
| Company: Genomic Health |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|